Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008476
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 0
---
Filed Pursuant to Section 424(b)(3)

Registration No. 333-269414

Prospectus Supplement No. 4

(To Prospectus Dated February 1, 2023)

<div align='center'>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

Up to 9,744,605 Shares of Common Stock Issuable Upon Conversion of 5% Senior Secured Convertible Notes

Up to 1,018,079 Shares of Common Stock Issuable Upon Exercise of Warrants</div>

This prospectus supplement No. 4 updates, amends and supplements the prospectus dated February 1, 2023 (as supplemented or amended from time to time, the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-269414).

This prospectus supplement is being filed to update, amend and supplement the information in the Prospectus with the information contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (the “Commission”) on February 26, 2025 (the “Annual Report”), and a consent from the auditor, Forvis Mazars, LLP, to include their audit report from the Annual Report (the “Auditors’ Consent”). Accordingly, we have attached the Annual Report and the Auditors’ Consent to this prospectus supplement.

The Prospectus and this prospectus supplement relate to the resale from time to time of (i) up to 9,744,605 shares of common stock (1,218,076 shares on a post 1-for-8 reverse split basis) underlying a $4.3 million convertible note (the “Convertible Note”), which shares represent 300% of the maximum number of shares of common stock issuable upon conversion of the Convertible Note, and (ii) 1,018,079 shares of common stock (127,260 shares on a post 1-for-8 reverse-split basis) issuable upon exercise of a warrant (the “Warrant”), each of which were issued on January 11, 2023 in a private placement to the selling stockholder named in the prospectus (the aggregate 10,762,684 shares of common stock (1,345,336 shares on a post 1-for-8 reverse split basis) being registered underlying the Convertible Note and Warrant, together, referred to as the